SOURCE-LINKED STUDY SUMMARY
Weight Regain After Stopping Semaglutide: STEP 1
PED EVIDENCE INTERPRETATION
What happens after semaglutide is stopped?
In this selected follow-up group, participants regained about two-thirds of their prior semaglutide-associated weight loss over one year. They remained 5.6% below baseline on average. Medication and structured lifestyle support both stopped. [1]
- Design
- Exploratory follow-up, not a new randomized withdrawal comparison
- Population
- 327 treatment completers; overweight or obesity, without diabetes
- Exposure
- Semaglutide 2.4 mg weekly or placebo for 68 weeks, then withdrawal
- Follow-up
- 52 weeks off treatment, ending at week 120
The evidence at a glance
| Time point | Prior semaglutide | Prior placebo | Uncertainty / meaning |
|---|---|---|---|
| Weeks 0–68 [1] | −17.3% | −2.0% | Before withdrawal |
| Weeks 68–120 [1] | +11.6 percentage points | +1.9 percentage points | Regain relative to original baseline weight |
| Weeks 0–120 [1] | −5.6% | −0.1% | Residual loss; SD 8.9 and 5.8 percentage points |
OUR READING OF THE EVIDENCE
What this changes
Maintenance deserves its own plan. Reaching a target weight does not establish that the conditions supporting that loss will persist after treatment ends. [1][2]
What it does not establish
This does not prove everyone regains all their weight or needs an unchanged dose forever. Tapering, lower-dose maintenance and continued structured lifestyle support were not tested here. [1]
Put it in context
STEP 4 helps isolate medication withdrawal
Lifestyle support continued in both groups. After the run-in, continued semaglutide produced another 7.9% loss versus 6.9% regain with placebo over 48 weeks, a difference of −14.8 percentage points (95% CI −16.0 to −13.5). Regain therefore cannot be explained solely by removing lifestyle support. [2]
Read the related study summaryWhy these designs should not be treated as identical
A randomized withdrawal comparison asks what continuing treatment changes. An off-treatment extension describes what followed withdrawal in selected completers. Those are complementary questions, with different limits on causal interpretation. [1][2]
Sources and transparency
STEP 1 was funded by Novo Nordisk. The extension included a subset of completers, which limits generalizability. [1]
Questions this study helps answer
Does everyone regain all the weight after stopping?
No. This is a group average from a selected extension cohort. Individual outcomes varied, and average weight remained below baseline at week 120. [1]
Did STEP 1 test tapering or a lower maintenance dose?
No. This extension followed withdrawal of medication and structured lifestyle support. It cannot determine whether tapering, lower-dose maintenance or continued intensive support changes regain. [1]
Original compact summary and study details
- What was studied
- Exploratory follow-up after semaglutide or placebo and the accompanying lifestyle intervention were stopped.
- Who / model studied
- 327 adults from the original trial, without diabetes, followed for one year after completing 68 weeks of treatment.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- Initial weight loss was 17.3% with semaglutide versus 2.0% with placebo. After stopping treatment, participants regained 11.6 versus 1.9 percentage points, leaving net losses of 5.6% versus 0.1%. Semaglutide participants regained about two-thirds of their prior loss, and most cardiometabolic improvements moved toward baseline.
- Limitations & context
- The extension was exploratory and included a subset of treatment completers. Both medication and lifestyle intervention were discontinued.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1111/dom.14725